Future prospects for primary hormone therapy in localized and locally advanced prostate cancer

Fernand Labrie, Mark S. Soloway, Hideyuki Akaza, Yoshihiko Hirao

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

The authors consider current and future prospects for primary hormone therapy in localized and locally advanced prostate cancer by comparing this form of treatment (hormone monotherapy) with neoadjuvant radiation therapy and radical prostatectomy. Neoadjuvant hormone therapy prior to radiation therapy has been proven effective in recent years, and currently the United States is showing a year-by-year increase in the use of androgen blocking agents during the early stage of prostate cancer. A survey of recent research findings, clearly showed that, for patients with localized prostate cancer, there is no significant difference in survival rate between hormone monotherapy and radical prostatectomy. In the future we can expect to see an increase in available treatment options for localized and locally advanced prostate cancer, with the optimal therapy for each individual patient to be selected by the attending physician in discussion with the patient.

Original languageEnglish (US)
Pages (from-to)771-777
Number of pages7
JournalActa Urologica Japonica
Volume49
Issue number12
StatePublished - Dec 1 2003

Keywords

  • Androgen blockade
  • Hormone therapy
  • Neoadjuvant therapy
  • Organ confined
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Future prospects for primary hormone therapy in localized and locally advanced prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Labrie, F., Soloway, M. S., Akaza, H., & Hirao, Y. (2003). Future prospects for primary hormone therapy in localized and locally advanced prostate cancer. Acta Urologica Japonica, 49(12), 771-777.